Skip to main content

Table 6 Incidence of drug related adverse events in safety analysis population

From: The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia

Drug related adverse events

Number (%) of subjects with ADRs

 

FMS/RSV

MFS

RSV

p-value

Total number (%)

4 (8.33)

3 (6.52)

5 (11.11)

0.755

Abdominal pain upper

-

1 (2.17)

-

 

Dyspepsia

1 (2.08)

-

-

 

Nausea

1 (2.08)

-

-

 

Headache

-

-

2 (4.44)

 

Pyrexia

1 (2.08)

-

-

 

Hepatitis

1 (2.08)

-

-

 

Hepatic enzyme increased

-

1 (2.17)

-

 

Hyperkalaemia

-

-

1 (2.22)

 

Insomnia

-

-

1 (2.22)

 

Pollakiuria

-

1 (2.17)

-

 

Pruritus

-

-

1 (2.22)

 
  1. ADRs adverse drug reactions, FMS/RSV fimasartan 120 mg/rosuvastatin 20 mg treatment, FMS fimasartan 120 mg alone treatment, RSV rosuvastatin 20 mg alone treatment
Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us